NIH-supported study pits BPH devices against drugs
This article was originally published in The Gray Sheet
Executive Summary
Medtronic and Urologix are among firms standing to benefit from a study comparing minimally invasive surgical treatment of benign prostatic hyperplasia (BPH) using transurethral needle ablation (TUNA) and transurethral microwave thermotherapy (TUMT) to drugs. Efficacy of the devices, offered by such firms as Medtronic (TUNA) and Urologix (TUMT), first approved by FDA in 1996, will be compared to a regimen of finasteride (Proscar) and the alpha-1 inhibitor doxazosin (Cardura). The study will be run by The Minimally Invasive Surgical Therapies (MIST) Consortium, supported in part by both firms, and will be funded by $15 mil. from the National Institute of Diabetes & Digestive & Kidney Diseases at NIH. The protocol will include three-to-five-year follow-up, roughly through July 2009, on more than 700 men with moderate to severe symptoms...
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.